Liposomal mitoxantrone for children and young adults with relapsed solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of chemotherapy (liposomal mitoxantrone) for children, adolescents, and young adults whose solid tumors have come back or not responded to treatment. The goal is to see if this combination regimen can help shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 and 24 years old.
- You have a solid tumor that has returned or is not responding to treatment, such as bone/soft tissue tumors or neuroblastoma.
- You have measurable tumors that can be seen on scans like CT or MRI.
- Your overall health is fairly good (Karnofsky score > 50 or ECOG ≤ 2).
- Your blood counts and liver/kidney function are within safe limits for this treatment.
- You have not had serious heart problems in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
This trial tests a liposomal form of mitoxantrone combined with other drugs for people with aggressive multiple myeloma (high-risk or spread outside the bone). The goal is to see if this approach helps control the cancer better.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
This trial tests a combination of three drugs (VIM and VIT) for children and young adults whose soft tissue sarcoma has come back or not responded to previous treatments. The goal is to see if this new combination can help shrink or control the tumor.
This study tests a stronger pre-transplant conditioning regimen—using a liposome form of mitoxantrone with standard chemotherapy—to help wipe out remaining AML cells before a stem cell transplant. It is for people with higher-risk AML or who still have measurable disease before transplant.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
Hear when a new Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.